Medline Inc. MDLN
34.70
0.04
0.12%
as of 25 Sep
- Market cap
- $45.5B
- P/E
- —
Follow MDLN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | — | — |
+3 more TTM periods Free account |
|
| 3.58% | 2.58% | 0.00% | — | ||
ROIC |
19.94% | 19.84% | 0.00% | 0.00% | |
Return on Tangible Assets |
5.13% | 7.21% | 0.00% | — | |
Average Days of Receivables |
44.98 | 46.78 | 0.00 | — | |
Free Cash Flow per Share |
2.69 | 2.79 | 4.18 | 0.00 | |
Free Cash Flow |
2,304.00 | 2,284.00 | 3,383.00 | 3,496.00 | |
Capital Expenditures |
(764.00) | (751.00) | (1,009.00) | (837.00) | |
Piotroski F-Score |
1.00 | 1.00 | 0.00 | — | |
| Other line items | |||||
Cash ROIC |
8.94% | 8.89% | 13.00% | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
18.32 | 0.00 | 0.00 | — | |
Days of Inventory on Hand |
81.93 | 0.00 | 0.00 | — | |
Tax Rate |
(0.02) | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
15.71% | 0.00% | — | — | |
Share Based Compensation of Revenue |
0.29% | 0.00% | — | — | |
Interest Coverage |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
4.36 | 3.14 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.40 | 0.39 | 0.56 | 0.00 | |
Capex/Depreciation |
(0.41) | (0.40) | (0.38) | (0.31) | |
Revenue per Share |
34.67 | 35.00 | 0.00 | — | |
Operating CF per Share |
3.58 | 3.71 | 5.42 | 0.00 | |
Capex per Share |
(0.89) | (0.92) | (1.25) | 0.00 | |
Capex to Sales |
0.03 | 0.03 | 0.00 | 0.00 | |
Net Profit Margin |
2.37% | 3.37% | — | — |
Columns are period end dates